CBIO Catalyst Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CBIO

Price (delayed)

$0.22

Market cap

$8.31M

P/E Ratio

1.05

Dividend/share

N/A

EPS

$0.21

Enterprise value

$208,162

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its protease engineering platform has generated ...

Highlights
CBIO's EPS has surged by 181% since the previous quarter and by 108% year-on-year
The net income has soared by 180% from the previous quarter and by 108% YoY
CBIO's quick ratio has surged by 63% since the previous quarter but it is down by 3.7% year-on-year
The company's equity has shrunk by 196% YoY and by 20% QoQ
CBIO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.catalystbiosciences.com
Peers: NRC NWBO

Key stats

What are the main financial stats of CBIO
Market
Shares outstanding
37.76M
Market cap
$8.31M
Enterprise value
$208,162
Valuations
Price to earnings (P/E)
1.05
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
0.03
EV/EBITDA
0.03
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
$6.92M
EBITDA
$7.04M
Free cash flow
-$26.76M
Per share
EPS
$0.21
Free cash flow per share
-$0.71
Book value per share
-$0.69
Revenue per share
$0
TBVPS
$0.5
Balance sheet
Total assets
$18.75M
Total liabilities
$11.39M
Debt
$0
Equity
-$25.95M
Working capital
$7.17M
Liquidity
Debt to equity
0
Current ratio
2.05
Quick ratio
2.58
Net debt/EBITDA
-1.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
16.2%
Return on equity
43.1%
Return on invested capital
498.6%
Return on capital employed
58.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CBIO stock price

How has the Catalyst Biosciences stock price performed over time
Intraday
-4.64%
1 week
-4.31%
1 month
3.77%
1 year
-82.26%
YTD
-58.29%
QTD
6.28%

Financial performance

How have Catalyst Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
$6.27M
Net income
$6.55M
Gross margin
N/A
Net margin
N/A
The net income has soared by 180% from the previous quarter and by 108% YoY
CBIO's operating income has surged by 173% since the previous quarter and by 108% year-on-year
CBIO's gross profit has surged by 100% since the previous quarter and by 100% year-on-year
CBIO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Growth

What is Catalyst Biosciences's growth rate over time

Valuation

What is Catalyst Biosciences stock price valuation
P/E
1.05
P/B
N/A
P/S
N/A
EV/EBIT
0.03
EV/EBITDA
0.03
EV/Sales
N/A
CBIO's EPS has surged by 181% since the previous quarter and by 108% year-on-year
The company's equity has shrunk by 196% YoY and by 20% QoQ
CBIO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Catalyst Biosciences business performance
Catalyst Biosciences's ROA has soared by 190% from the previous quarter and by 114% YoY
The ROE has soared by 129% year-on-year
CBIO's ROIC has soared by 121% YoY

Dividends

What is CBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBIO.

Financial health

How did Catalyst Biosciences financials performed over time
CBIO's total assets is 65% greater than its total liabilities
CBIO's quick ratio has surged by 63% since the previous quarter but it is down by 3.7% year-on-year
CBIO's total assets has dropped by 53% year-on-year and by 34% since the previous quarter
Catalyst Biosciences's debt is 100% higher than its equity
The company's equity has shrunk by 196% YoY and by 20% QoQ
Catalyst Biosciences's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.